News Agency
The Times

Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA

  • Written by PR Newswire

HONG KONG, July 29, 2024 /PRNewswire/ -- Akeso (9926.HK) is delighted to announce that the supplemental biologics license application (sBLA) for its independently developed, world's first-in-class PD-1/VEGF bispecific antibody drug, 依达方® (generic name: ivonescimab Injection), as a monotherapy for first-line treatment of...

Read more: Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA

Why Businesses Rely On Accountants in Melbourne For Financial Success

Managing finances effectively is essential for individuals, business owners, investors, and growing organisations. Financial decisions influence profitability, compliance, cash flow, and long-term wealth creation, making professional financial guidance an important part of successful planning. Many individuals and businesses choose to... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion